1. Total Serum Bilirubin within 3 Months of Hepatoportoenterostomy Predicts Short-Term Outcomes in Biliary Atresia
- Author
-
Benjamin L. Shneider, John C. Magee, Saul J. Karpen, Elizabeth B. Rand, Michael R. Narkewicz, Lee M. Bass, Kathleen Schwarz, Peter F. Whitington, Jorge A. Bezerra, Nanda Kerkar, Barbara Haber, Philip Rosenthal, Yumirle P. Turmelle, Jean P. Molleston, Karen F. Murray, Vicky L. Ng, Kasper S. Wang, Rene Romero, Robert H. Squires, Ronen Arnon, Averell H. Sherker, Jeffrey Moore, Wen Ye, Ronald J. Sokol, Estella Alonso, Elizabeth Kaurs, Sue Kelly, Kevin Bove, James Heubi, Alexander Miethke, Greg Tiao, Julie Denlinger, Andrea Ferris, Amy Feldman, Cara Mack, Frederick Suchy, Shikha Sundaram, Johan Van Hove, Michelle Hite, Susanna Kantor, Todd Miller, Julia Smith, Becky VanWinkle, Kathleen Loomes, Henry Lin, David Piccoli, Pierre Russo, Nancy Spinner, Lindsay Brown, Emily Elgert, Jessi Erlichman, Feras Alissa, Douglas Lindblad, George Mazariegos, Roberto Ortiz-Aguayo, David Perlmutter, Rakesh Sindhi, Veena Venkat, Jerry Vockley, Kathy Bukauskas, Adam Kufen, Madeline Schulte, Laura Bull, Shannon Fleck, Camille Langlois, Jeffery Teckman, Vikki Kociela, Stacy Postma, Kathleen Harris, Molly Bozic, Girish Subbarao, Beth Byam, Ann Klipsch, Cindy Sawyers, Simon Horslen, Evelyn Hsu, Kara Cooper, Melissa Young, Binita Kamath, Maria DeAngelis, Constance O'Connor, Krista VanRoestel, Arpita Parmar, Claudia Quammie, Kelsey Hung, Stephen Guthery, Kyle Jensen, Ann Rutherford, Nanda Kerker, Sonia Michail, Danny Thomas, Catherine Goodhue, Nikita Gupta, Mariam Vos, Liezl de la Cruz-Tracey, Dana Hankerson-Dyson, Rita Tory, Taieshia Turner-Green, Allison Wellons, Mary Brandt, Milton Finegold, Sanjiv Harpavat, Paula Hertel, Daniel Leung, Loriel Liwanag, Richard Thompson, Sherry Brown, Edward Doo, Jay Hoofnagle, Sherry Hall, Rebecca Torrance, Jameisha Brown, Kimberly Kafka, Robert Merion, and Cathie Spino
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Area under the curve ,Liver transplantation ,medicine.disease ,Hepatoportoenterostomy ,Gastroenterology ,Surgery ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Multicenter study ,Biliary atresia ,030225 pediatrics ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Biomarker (medicine) ,030211 gastroenterology & hepatology ,business ,Prospective cohort study - Abstract
Objectives To prospectively assess the value of serum total bilirubin (TB) within 3 months of hepatoportoenterostomy (HPE) in infants with biliary atresia as a biomarker predictive of clinical sequelae of liver disease in the first 2 years of life. Study design Infants with biliary atresia undergoing HPE between June 2004 and January 2011 were enrolled in a prospective, multicenter study. Complications were monitored until 2 years of age or the earliest of liver transplantation (LT), death, or study withdrawal. TB below 2 mg/dL (34.2 μM) at any time in the first 3 months (TB Results Fifty percent (68/137) of infants had TB P P P P P = .0002), LT (OR 12.4, 95% CI 5.3-28.7, P P Conclusions Infants whose TB does not fall below 2.0 mg/dL within 3 months of HPE were at high risk for early disease progression, suggesting they should be considered for LT in a timely fashion. Interventions increasing the likelihood of achieving TB Trial registration ClinicalTrials.gov: NCT00061828 and NCT00294684.
- Published
- 2016
- Full Text
- View/download PDF